medigraphic.com
Instituto Nacional de Salud Pública

2019, Número 3

<< Anterior Siguiente >>

salud publica mex 2019; 61 (3)


Tuberculosis y cáncer de pulmón

Molina-Romero C, Arrieta O, Hernández-Pando R

Idioma: Ingles.
Referencias bibliográficas: 46
Paginas: 286-291
Archivo PDF: 295.64 Kb.


RESUMEN

Objetivo. Describir los estudios que documentan la relación entre el cáncer de pulmón (CP) y la tuberculosis pulmonar (Tb) y sus posibles mecanismos moleculares. Material y métodos. Se revisaron bases de datos de publicaciones, usando como palabras clave CP y Tb. Resultados. Se ha propuesto que la inflamación crónica en el pulmón provocada por la Tb podría producir actividad clastogénica. Otra posibilidad es la transferencia lateral de genes; Mycobacterium tuberculosis (MTb) es un organismo intracelular facultativo cuyo DNA podría integrarse al material genético del epitelio bronquial induciendo transformación neoplásica. Conclusión. Existen evidencias epidemiológicas, particularmente en países asiáticos, que documentan la relación entre CP y Tb. MTb podría desempeñar un papel activo en la transformación neoplásica cuyo mecanismo debe de ser elucidado.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Organización Mundial de la Salud [internet]. OMS; c2018 [cited 2018 Nov]. Tuberculosis; [about 6 screens]. Available from: http://www.who.int/ mediacentre/factsheets/fs104/es/index.html

  2. Organización Panamericana de la Salud [internet]. Washington: PAHO; c2017. Informe país: México. Salud en las Américas 2017; [about 4 screens] [cited November, 2018]. Available from: https://www.paho.org/salud-enlas- americas-2017/?post_t_es=mexico&lang=es

  3. Arrieta O, Guzman-de Alba E, Alba-Lopez LF, Acosta-Espinoza A, Alatorre-Alexander J, Alexander-Meza JF, et al. Consenso nacional de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. Rev Invest Clin. 2013;65(suppl 1):S5-84.

  4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. https:// doi.org/10.1002/ijc.29210

  5. Arrieta O, Campos-Parra AD, Zuloaga C, Aviles A, Sanchez-Reyes R, Manriquez ME, et al. Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure. J Thorac Oncol. 2012;7(8):1228-34. https://doi. org/10.1097/JTO.0b013e3182582a93

  6. Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(suppl 5):e1S-29S. https://doi.org/10.1378/chest.12-2345

  7. Chang MH, You SL, ChenCJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101(19):1348-55. https://doi. org/10.1093/jnci/djp288

  8. Martel C de, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607-15. https://doi. org/10.1016/S1470-2045(12)70137-7

  9. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens--Part B: biological agents. Lancet Oncol. 2009;10(4):321-2. https://doi.org/10.1016/S1470-2045(09)70096-8

  10. International Agency for Research on Cancer. A review of carcinogen— Part B: Biological Agents. Monographs on the evaluation of carcinogenic risks to humans. Lyon: IARC, 2012. [cited November, 2018] Available from: https://monographs.iarc.fr/wp-content/uploads/2018/06/ mono100B.pdf

  11. Liang HY, Li XL, Yu XS, Guan P, Yin ZH, He QC, et al. Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: a systematic review. Int J Cancer. 2009;125(12):2936-44. https://doi. org/10.1002/ijc.24636

  12. Cicenas S, Vencevicius V. Lung cancer in patients with tuberculosis. World J Surg Oncol. 2007;5:22. https://doi.org/10.1186/1477-7819-5-22

  13. Littman AJ, Thornquist MD, White E, Jackson LA, Goodman GE, Vaughan TL. Prior lung disease and risk of lung cancer in a large prospective study. Cancer Causes Control. 2004;15(8):819-27. https://doi. org/10.1023/B:CACO.0000043432.71626.45

  14. Wu CY, Hu HY, Pu CY, Huang N, Shen HC, Li CP, et al. Pulmonary tuberculosis increases the risk of lung cancer: a population-based cohort study. Cancer. 2011;117(3):618-24. https://doi.org/10.1002/cncr.25616

  15. Zheng W, Blot WJ, Liao ML, Wang ZX, Levin LI, Zhao JJ, et al. Lung cancer and prior tuberculosis infection in Shanghai. Br J Cancer. 1987;56(4):501-4. https://doi.org/10.1038/bjc.1987.233

  16. Shiels MS, Albanes D, Virtamo J, Engels EA. Increased risk of lung cancer in men with tuberculosis in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev. 2011;20(4):672-8. https://doi.org/10.1158/1055-9965.EPI-10-1166

  17. Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PLoS One. 2011;6(3):e17479. https://doi.org/10.1371/journal.pone.0017479

  18. Everatt R, Kuzmickiene I, Davidaviciene E, Cicenas S. Incidence of lung cancer among patients with tuberculosis: a nationwide cohort study in Lithuania. Int J Tuberc Lung Dis. 2016;20(6):757-63. https://doi. org/10.5588/ijtld.15.0783

  19. Engels EA, Shen M, Chapman RS, Pfeiffer RM, Yu YY, He X, et al. Tuberculosis and subsequent risk of lung cancer in Xuanwei, China. Int J Cancer. 2009;124(5):1183-7. https://doi.org/10.1002/ijc.24042

  20. Yu YH, Liao CC, Hsu WH, Chen HJ, Liao WC, Muo CH, et al. Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. J Thorac Oncol. 2011;6(1):32-7. https://doi.org/10.1097/ JTO.0b013e3181fb4fcc

  21. Heuvers ME, Aerts JG, Hegmans JP, Veltman JD, Uitterlinden AG, Ruiter R, et al. History of tuberculosis as an independent prognostic factor for lung cancer survival. Lung Cancer. 2012;76(3):452-6. https://doi. org/10.1016/j.lungcan.2011.12.008

  22. Stokes RW, Waddell SJ. Adjusting to a new home: Mycobacterium tuberculosis gene expression in response to an intracellular lifestyle. Future Microbiol. 2009;4(10):1317-35. https://doi.org/10.2217/fmb.09.94

  23. Saunders BM, Britton WJ. Life and death in the granuloma: immunopathology of tuberculosis. Immunol Cell Biol. 2007;85(2):103-11. https:// doi.org/10.1038/sj.icb.7100027

  24. Marks GB, Bai J, Simpson SE, Sullivan EA, Stewart GJ. Incidence of tuberculosis among a cohort of tuberculin-positive refugees in Australia: reappraising the estimates of risk. Am J Respir Crit Care Med. 2000;162(5):1851-4. https://doi.org/10.1164/ajrccm.162.5.2004154

  25. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7. https://doi.org/10.1038/nature01322

  26. Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther. 2008;8(4):605-15. https://doi. org/10.1586/14737140.8.4.605

  27. Dheda K, Booth H, Huggett JF, Johnson MA, Zumla A, Rook GA. Lung remodeling in pulmonary tuberculosis. J Infect Dis. 2005;192(7):1201-9. https://doi.org/10.1086/444545

  28. Cooper AM, Khader SA. The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol Rev. 2008;226(1):191-204. https://doi.org/10.1111/j.1600-065X.2008.00702.x

  29. Auerbach O, Garfinkel L, Parks VR. Scar cancer of the lung: increase over a 21 year period. Cancer. 1979;43(2):636-42. https://doi.org/10.1002/1097-0142(197902)43:2<636::AIDCNCR2820430234> 3.0.CO;2-7

  30. Ardies CM. Inflammation as cause for scar cancers of the lung. Integr Cancer Ther. 2003;2(3):238-46. https://doi.org/10.1177/1534735403256332

  31. Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer. 2010;10(12):878- 89. https://doi.org/10.1038/nrc2961

  32. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-45. https://doi.org/10.1016/S0140- 6736(00)04046-0

  33. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol. 2012;30:677-706. https://doi. org/10.1146/annurev-immunol-020711-075008

  34. Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13(11):800-12. https://doi.org/10.1038/nrc3610

  35. Schroder G, Schuelein R, Quebatte M, Dehio C. Conjugative DNA transfer into human cells by the VirB/VirD4 type IV secretion system of the bacterial pathogen Bartonella henselae. Proc Natl Acad Sci USA. 2011;108(35):14643-8. https://doi.org/10.1073/pnas.1019074108

  36. Koehler JE, Sanchez MA, Garrido CS, Whitfeld MJ, Chen FM, Berger TG, et al. Molecular epidemiology of bartonella infections in patients with bacillary angiomatosis-peliosis. N Engl J Med. 1997;337(26):1876-83. https://doi.org/10.1056/NEJM199712253372603

  37. Riley DR, Sieber KB, Robinson KM, White JR, Ganesan A, Nourbakhsh S, et al. Bacteria-human somatic cell lateral gene transfer is enriched in cancer samples. PLoS Comput Biol. 2013;9(6):e1003107. https://doi. org/10.1371/journal.pcbi.1003107

  38. da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6:49-69. https://doi.org/10.1146/annurevpathol- 011110-130206

  39. Campos-Parra AD, Zuloaga C, Manriquez ME, Aviles A, Borbolla- Escoboza J, Cardona A, et al. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. Am J Clin Oncol. 2015;38(1):33-40. https://doi.org/10.1097/ COC.0b013e318287bb23

  40. Arrieta O, Cardona AF, Martin C, Mas-Lopez L, Corrales-Rodriguez L, Bramuglia G, et al. Updated frequency of EGFR and KRAS mutations in nonsmall-cell lung cancer in Latin America: The Latin-American consortium for the Investigation of lung cancer (CLICaP). J Thorac Oncol. 2015;10(5):838-43. https://doi.org/10.1097/JTO.0000000000000481

  41. Sakurada A, Shepherd FA, Tsao MS. Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. Clinical lung cancer. 2006;7(Suppl 4):S138-44. https://doi. org/10.3816/CLC.2006.s.005

  42. Luo YH, Wu CH, Wu WS, Huang CY, Su WJ, Tsai CM, et al. Association between tumor epidermal growth factor receptor mutation and pulmonary tuberculosis in patients with adenocarcinoma of the lungs. Journal Thorac Oncol. 2012;7(2):299-305. https://doi.org/10.1097/ JTO.0b013e31823c588d

  43. Chang CH, Lee CH, Ho CC, Wang JY, Yu CJ. Gender-based impact of epidermal growth factor receptor mutation in patients with nonsmall cell lung cancer and previous tuberculosis. Medicine (Baltimore). 2015;94(4):e444. https://doi.org/10.1097/MD.0000000000000444

  44. Ruano MJ, Hernandez-Hernando S, Jimenez A, Estrada C, Villalobo A. Nitric oxide-induced epidermal growth factor-dependent phosphorylations in A431 tumour cells. Eur J Biochem. 2003;270(8):1828-37. https:// doi.org/10.1046/j.1432-1033.2003.03546.x

  45. Zhang J, Iwanaga K, Choi KC, Wislez M, Raso MG, Wei W, et al. Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. Cancer Prev Res (Phila). 2008;1(3):201-7. https://doi.org/10.1158/1940- 6207.CAPR-08-0014

  46. Nalbandian A, Yan BS, Pichugin A, Bronson RT, Kramnik I. Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control. Oncogene. 2009;28(17):1928-38. https://doi. org/10.1038/onc.2009.32




2020     |     www.medigraphic.com